ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Convergence Pharmaceuticals, a biotech firm formed out of assets from GlaxoSmithKline’s analgesic drug pipeline, has launched with $35.4 million in financing. The Cambridge, England-based biotech starts off with a collection of six early-stage compounds and two drugs in clinical studies—CNV1014802 and CNV2197944, voltage-gated calcium channel blockers for neuropathic pain. Simon Tate, former vice president for GSK’s pain and epilepsy discovery unit, will serve as Convergence’s chief scientific officer. For GSK, the divestiture of the compounds is part of a larger effort to trim R&D. GSK retains an 18% stake in the firm.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X